Introduction
Build awareness on Mounjaro - the first GIP & GLP-1 receptor agonist through an engaging discussion with investigators covering:
• MoA
• Phase Ill SURPASS trial program.
Objectives
.
This Course For :
Physician
( Endocrinology & Metabolism )
Resident / Fellow
( Endocrinology & Metabolism )
Speaker
Dr. Bruno Halpern
Chief-Director, Obesity Centre, Hospital 9 de Julho, Sao Paulo
Prof. Dr. Juris J. Meler
Researcher, Diabetes Center Bochum-Hattingen,
St. Josef Hospital, Bochum
Dr. Santiago Tote
Consultant, Dep. of Endocrinology, Uni. Hospital Son Espases, Ass. Professor University Illes Balears
Note : This content is sponsored and approved by Eli Lilly and company (Lilly). This content is intellectual property of Lilly and its reproduction needs Lilly prior permission.
05 Jul 2023 To 05 Jul 2023 -
10:00 PM To 11:00 PM 
Certificate Available 
Online
- 4
Add to Calendar
07/05/2023 10:00 PM
07/05/2023 11:00 PM
Asia/ Riyadh
The first GIP & GLP-1 receptor agonist for T2D treatment
The first GIP & GLP-1 receptor agonist for T2D treatment
https://medicalacademy.org/portal/event/view/1978
